Peptable

Comparison

CJC-1295 vs SS-31

Also see:

CJC-1295SS-31

Function

While CJC-1295 is used in research to chronically elevate endogenous growth hormone and IGF-1 levels, enabling studies of body composition, metabolic, and anti-aging effects of prolonged GH exposure10, SS-31 improves mitochondrial bioenergetics, reduces oxidative stress, and shows protective effects in models of ischemia-reperfusion, neurodegeneration, and other mitochondrial disorders4637137.

Mechanism

While CJC-1295 works as a tetrasubstituted 29-amino-acid analog of GHRH(1–29) that acts as a potent agonist at the GHRH receptor and, in its DAC form, covalently binds serum albumin to extend half-life from minutes to days, resulting in sustained pulsatile GH and IGF-1 increase1082, SS-31 is a mitochondria-targeted tetrapeptide, d-Arg-dimethylTyr-Lys-Phe-NH2, that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure, improving electron transport, and reducing ROS production4637137143.

Receptor

CJC-1295

Growth hormone–releasing hormone receptor (GHRHR) on anterior pituitary somatotrophs1094103

SS-31

Cardiolipin-rich inner mitochondrial membrane; interacts with cardiolipin and associated mitochondrial proteins rather than a classical cell-surface receptor46137143

Organism or Origin

CJC-1295

Synthetic peptide based on human hypothalamic GHRH10120

SS-31

Fully synthetic Szeto–Schiller tetrapeptide; not encoded in the genome4637

Gene

CJC-1295

GHRH

SS-31

Not assigned in the current dataset.

Summary

CJC-1295 and SS-31 are noticeably different, with limited direct overlap in their usual biological context. Both are often discussed in Aging and longevity contexts, while CJC-1295 is more of a hormone peptide and SS-31 is better described as a mitochondrial peptide. They also influence different molecular systems, with CJC-1295 tracking more closely to Growth hormone axis while SS-31 centers more on Mitochondrial membrane. CJC-1295 has a more synthetic analog origin, while SS-31 is closer to synthetic design background with CJC-1295 in Preclinical development and SS-31 in Clinical phase 2. CJC-1295 takes the form of a peptide conjugate, whereas SS-31 is closer to a linear peptide, while their sequence patterns also diverge, with CJC-1295 showing alpha-helical domain features and SS-31 showing cationic amphipathic features.

Sources

10CJC-1295: Long-Acting GHRH Analog - Alpha Carbon Labs, https://alphacarbonlabs.com/blog/cjc-1295-long-acting-ghrh-analog
82CJC-1295 no DAC 5mg (Mod GRF 1-29), https://www.peptidesciences.com/mod-grf-1-29-5mg-cjc-1295-no-dac
94Growth-hormone-releasing hormone receptor - Wikipedia, https://en.wikipedia.org/wiki/Growth-hormone-releasing_hormone_receptor
103Growth-hormone-releasing hormone receptor - Wikipedia, https://en.wikipedia.org/wiki/Growth_hormone_releasing_hormone_receptor
120Growth hormone–releasing hormone - Wikipedia, https://en.wikipedia.org/wiki/Growth_hormone%E2%80%93releasing_hormone
46Discovery of novel SS-31 (d-Arg-dimethylTyr-Lys-Phe-NH2 ... - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11409442/
56Discovery of novel SS-31 (d-Arg-dimethylTyr-Lys-Phe-NH2 ..., https://pubs.rsc.org/en/content/articlelanding/2024/ra/d4ra05517a
137Mitochondrial protein interaction landscape of SS-31 | PNAS, https://www.pnas.org/doi/10.1073/pnas.2002250117
143SS-31 Peptide: Mitochondrial Repair for Energy and Longevity, https://revolutionhealth.org/blogs/news/peptide-therapy-ss-31